Design and synthesis of new orally active inhibitors of human neutrophil elastase

Bioorg Med Chem. 2001 May;9(5):1307-23. doi: 10.1016/s0968-0896(01)00007-4.

Abstract

To identify new orally active inhibitors, further modification of 1 (ONO-6818) was performed. Peptidic derivatives 4b, 4c and 4n showed more potent inhibitory activity than nonpeptidic derivatives 3a-c. As a result, a series of peptidic inhibitors, 4a-s and 5a-v, were discovered. Among these N-aryl derivatives 5a-g, 5i, 5m and 5o-v showed oral activity. Their oral activity showed good correlation with their metabolic stability. Compounds 5h and 5j-l, which were extremely metabolically unstable in hamster plasma, did not show oral activity. Oral activity was considered to be determined by a combination of at least two factors: oral absorption and metabolic stability.

MeSH terms

  • Administration, Oral
  • Animals
  • Cricetinae
  • Drug Design
  • Drug Stability
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / metabolism
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hydrolysis
  • Leukocyte Elastase / antagonists & inhibitors*
  • Leukocyte Elastase / metabolism
  • Oxadiazoles / chemical synthesis*
  • Oxadiazoles / chemistry
  • Oxadiazoles / metabolism
  • Oxadiazoles / pharmacology*
  • Peptides / chemical synthesis
  • Peptides / metabolism
  • Pyrimidinones / chemical synthesis*
  • Pyrimidinones / chemistry
  • Pyrimidinones / metabolism
  • Pyrimidinones / pharmacology*

Substances

  • Enzyme Inhibitors
  • ONO 6818
  • Oxadiazoles
  • Peptides
  • Pyrimidinones
  • Leukocyte Elastase